You are here: Home: LCU 2 | 2006 : Interview: Select publications

SELECT PUBLICATIONS

Anonymous. ZD6474 headed for phase III trials in the fall. Oncology (Williston Park) 2005;19(9):1140-2. No abstract available

Douillard J et al. ANITA: Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small-cell lung cancer (NSCLC) patients (pts): Final results after 70-month median follow-up on behalf of the Adjuvant International Trialist Association. Proc ASCO 2005;Abstract 7013.

Gatzemeier U et al. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer. Proc ASCO 2004;Abstract 7010.

Giaccone G et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial — INTACT 1. J Clin Oncol 2004;22(5):777-84. Abstract

Giantonio BJ et al. High-dose bevacizumab in combination with FOLFOX4 improves survival in patients with previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. Presentation. ASCO GI 2005;Abstract 169a.

Herbst RS et al. Clinical cancer advances 2005: Major research advances in cancer treatment, prevention, and screening — A report from the American Society of Clinical Oncology. J Clin Oncol 2006;24(1):190-205. Abstract

Herbst R et al. ZD6474 plus docetaxel in patients with previously treated NSCLC: Results of a randomized placebo-controlled Phase II trial. Presentation. Proceedings from the 11^th World Conference on Lung Cancer 2005a;Abstract O-100.

Herbst RS et al; TRIBUTE Investigator Group. TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005b;23(25):5892-9. Abstract

Herbst RS et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small- cell lung cancer. J Clin Oncol 2005c;23(11):2544-55. Abstract

Herbst RS et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial — INTACT 2. J Clin Oncol 2004;22(5):785-94. Abstract

Heymach JV et al. A randomized, placebo-controlled phase II trial of ZD6474 plus docetaxel in patients with NSCLC. Proc ASCO 2005;Abstract 3023.

Johnson BE et al. Preliminary phase II safety evaluation of ZD6474, in combination with carboplatin and paclitaxel, as 1st-line treatment in patients with NSCLC. Proc ASCO 2005;Abstract 7102.

Lee JS et al. Paclitaxel/carboplatin chemotherapy as primary treatment of brain metastases in non-small cell lung cancer: A preliminary report. Semin Oncol 1997;24(4 Suppl 12):12-55. Abstract

Miller VA et al. EGFR mutation, immunohistochemistry (IHC) and chromogenic in situ hybridization (CISH) as predictors of sensitivity to erlotinib and gefitinib in patients (pts) with NSCLC. Proc ASCO 2005;Abstract 7031.

Natale R et al. A comparison of the antitumour efficacy of ZD6474 and gefitinib (Iressa) in patients with NSCLC: Results of a randomized, double-blind Phase II study. Presentation. Proceedings from the 11th World Conference on Lung Cancer 2005;Abstract O-103.

Pham D et al. Use of cigarette smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinoma. J Clin Oncol 2006;24(11):1700-4. Abstract

Piccart-Gebhart MJ et al; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353(16):1659- 72. Abstract

Romond EH et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353(16):1673-84. Abstract

Sandler AB et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) trial — E4599. Proc ASCO 2005;Abstract 4.

 

Table of Contents

Top of Page